Pharmaceutical

First targeted alpha therapy wins FDA breakthrough device designation

RadioMedix and Orano Med’s radioligand therapy AlphaMedix (lead-212-Dotamtate) is currently in a Phase II trial.

Feb 12, 2024 - 18:00
First targeted alpha therapy wins FDA breakthrough device designation
RadioMedix and Orano Med’s radioligand therapy AlphaMedix (lead-212-Dotamtate) is currently in a Phase II trial.
Read the original article

Tags:

Previous Article

Disc wins orphan drug tag for rare blood cancer  

Next Article

CSL’s ‘big’ post-heart attack drug fails in Phase III trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Risk adjusted net present value: What is the current va...

Mar 13, 2024

STAT+: Pharmalittle: Weight loss drugs cost much more in the U.S.; PBMs win a key victory over an Oklahoma law

STAT+: Pharmalittle: Weight loss drugs cost much more i...

Aug 19, 2023

STAT+: Pharma industry showers House GOP doctor with campaign cash

STAT+: Pharma industry showers House GOP doctor with ca...

Aug 3, 2023